Accelerating and Scaling Biomanufacturing with Superior Quality in Ireland
With USD 9.9 million investment in new biopharmaceutical production facilities in Ireland over the previous ten years for new biotech manufacturing facilities, Ireland has recently become a place of choice for biopharmaceutical manufacturing. There are manufacturing facilities here for nine of the top ten pharmaceutical firms in the world, including Novartis, AbbVie, Janssen, Pfizer, Sanofi, GlaxoSmithKline, MSD, Bristol-Myers Squibb, and Takeda.
For instance, AstraZeneca invested USD 64 million on Irish manufacturing and R&D growth in June 2022; this will increase Alexion's capacity to produce drug substances in Ireland. The manufacturing facility for Johnson & Johnson in Ringaskiddy, Ireland finished a USD 354 million expansion, and now it has plans to increase the site's capacity even further. At its facility in Cork, Merck kGaA will invest more than USD 421 million in May 2022 to increase its production capabilities for membrane and filtering. Additionally, Takeda is establishing a single-use facility for the company's rare disease portfolio, MSD is building a facility to manufacture Keytruda, and BMS will manufacture its immuno-oncology drugs at a new USD 900 million plant in Dublin.
There are no indicators that investment in Ireland's biomanufacturing industry will decrease. The country's existing businesses are expanding their facilities, and new businesses are trying to establish themselves on the Emerald Isle. One such company is WuXi Biologics from China, which intends to construct the largest single-use manufacturing facility in the world in Dundalk, Ireland, as a new vaccine manufacturing facility.
Ireland’s strength in the bio manufacturing sector is down to a number of factors, and, whilst tax incentives are important, they are not the ultimate factor. The pharma industry is a prime example of what Moran refers to as the "knowledge-based sector," which was the focus of government expenditure and initiatives. Consider the Irish government's funding of the University College Dublin-based National Institute for Bioprocessing Research & Training (NIBRT). It is currently one of the top institutions in the world for training courses to support sophisticated biomanufacturing procedures.
IDA Ireland anticipates ongoing investment in 2021 despite the epidemic. The organization is starting a new "Strategy 2021-2024" with a focus on five pillars: growth, transformation, regions, sustainability, and impact. This strategy aims to attract 800 investments and create 50,000 new employment. The Irish government is devoted to keeping up its investments in research and education to make sure that Ireland continues to be a popular choice for new biotechnology manufacturing enterprises.
Industry 4.0 and Smart Manufacturing
Cell Line Development & Engineering and Cell Culture
Innovation in Product Purification & Concentration
Bioprocessing Excellence & Best Practices
Limited Super (By 30th Nov 2023) £ 850 Limited Special (By 22nd Dec 2023) £ 1,050 Early Bird (By 30th Jan 2024) £ 1,250 Standard Price £ 1,450
Limited Group Packages
Limited Super (By 30th Nov 2023) £ 2,050 Limited Special (By 22nd Dec 2023) £ 2,250 Early Bird (By 30th Jan 2024) £ 2,450 Standard Price £ 2,650
Group Discount for Solution Providers & General Public: Buy 3 and get 10% off, Buy 5 get 20% off, Buy 6 and above, get 25% off
This conference was long overdue in Singapore and critical to making sure that CCT understands current challenges facing our Asian based clients. This allows us to quickly provide new or turn-key solutions and products that meet their needs.
Cold Chain Technologies
BMA was an excellently organised event and as a sponsor, participating was very valuable in meeting new connections and engaging with existing customers & contacts. I would recommend anyone involved in the regional biologics industry to participate in the event.
With the many restrictions and the need to hold the event onsite and online, I do think this event is well planned and held. Easy registration. Spacious, simple and professional settings. All the staffs are very friendly and helpful too. Thank you!
West Pharmaceutical Services
Bioworkshops appreciate the effort IMAPAC invested to restore a strong In-person participation to this hybrid event, bringing together many of the biologics manufacturing leaders from Asia along and global experts.
The conference was a great success and fruitful.
Fantastic conference with professional team.
Blue Blood Biotech
Informative session. Exhibition was well targeted and diverse. Presenters shared latest development
It was an awesome experience to interact with so many energetic young professionals around the globe and share technical information. I want to express my heartfelt gratitude to the organizer for such a great event!
It was great to attend the session physically, and have some exchange with industry players and exchange ideas. Thanks IMAPAC for great organisation!
EVF Project Process Manufacturing Leader
Great forum for face to face interactions and for exchange of ideas and information.
The entire event was managed flawlessly by the Organizers. I personally did not face any technical glitches despite this even was organized in a hybrid manner. Almost every speaker gave a high quality presentation which was very insightful.
It was really great experience for me to be associated with IMAPAC which organizes high standard conference. Speakers from various domains/fields are thoughtfully chosen & they have delivered the relevant fields of present post-covid pandemic biologics scenario.
Serum Institute Of India Pvt. Limited
A well organized ambitious meeting. I hope it will continue to develop in the future.